COMMENT: Combinations of agents are being tried for pulmonary arterial hypertension (PAH)- a serious illness with a limited life expectancy. The clinical study below shows that the combination of a PDE5 inhibitor, tadalafil with bosentan, an agent already in use for PAH leads to the significant reduction in exposure of tadalafil because of the induction [...]
Filed under: Cytochrome P450, Drug Interactions, Personalized Medicine | Tagged: bosentan, CYP, CYP3A4, Cytochrome P450, endothelin receptor antagonist, PAH, Personalized Medicine, pharmacokinetic, phosphodiesterase, tadalafil | Leave a Comment »
